Burcon NutraScience Corp.
- WKN: 157793
- ISIN: CA1208311029
- Land: Kanada
Nachricht vom 16.01.2019 | 14:30
Burcon NutraScience Corp.: BURCON ANNOUNCES BOARD CHANGE AND APPOINTMENTS
DGAP-News: Burcon NutraScience Corp. / Key word(s): Personnel
BURCON ANNOUNCES BOARD CHANGE AND APPOINTMENTS
Vancouver, British Columbia, January 15, 2019 - Burcon NutraScience Corporation (TSX: BU) ("Burcon" or the "Corporation"), announces that effective today, Dr. Allan Yap has decided to step down from his positions as Chairman, director and Chief Executive Officer of the Corporation for personal reasons. The board of directors of Burcon (the "Board") is pleased to announce that Dr. Lorne Tyrrell has been appointed as Chairman of the Board and Mr. Johann Tergesen has been appointed as the Corporation's Chief Executive Officer.
"Dr. Allan Yap was instrumental in the founding of Burcon serving as Chairman, director and as chief executive officer for more than nineteen years. The Board is grateful for his guidance and leadership over the years," said Dr. Lorne Tyrrell, adding, "Allan made significant contributions to Burcon during his tenure."
On January 14, 2019, Large Scale Investments Limited, a company wholly-owned by Burcon director Mr. Alan Chan, announced that it had acquired from Dr. Yap 1,566,719 common shares of Burcon. The total number of Burcon shares, which Mr. Chan is now deemed to beneficially own post-acquisition of Dr. Yap's shares is 11,433,287, which represents 26.02% of the issued and outstanding shares of Burcon.
Dr. Tyrrell first joined Burcon's board of directors in December 2009 and was appointed Lead Director in February 2016 and chaired Board meetings in Dr. Yap's absence. As Lead Director, Dr. Tyrrell also acted as liaison between the Board and management of Burcon. Dr. Tyrrell is the Glaxo SmithKline Chair in Virology in the Department of Medical Microbiology and Immunology at the University of Alberta. Since 1986, he has focused his research on viral hepatitis. Supported by Canadian Institute of Health Research and Glaxo Canada, Dr. Tyrrell's work on the development of antiviral therapy resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection - lamivudine - in 1998. Dr. Tyrrell holds more than 50 international patents for his studies on viral hepatitis. Dr. Tyrrell was Dean of the Faculty of Medicine and Dentistry from 1994 - 2004 at the University of Alberta and is currently the Chair of the Board of Directors of the Gairdner Foundation. The Canada Gairdner International Awards recognizes excellence in medical science research globally. Dr. Tyrrell has received numerous prestigious awards including the Gold Medal of the Canadian Liver Foundation (2000), the FNG Starr Award of the Canadian Medical Association (2004), the Principal Award of the Manning Awards Foundation (2005) and the Queen Elizabeth II Diamond Jubilee Medal (2012). Dr. Tyrrell was appointed Officer of the Order of Canada in 2002. In April 2010, Dr. Tyrrell was appointed as the inaugural director of the Li Ka Shing Institute of Virology at the University of Alberta. On April 28, 2011, Dr. Tyrrell was inducted to the Canadian Medical Hall of Fame. In 2015, he was awarded the Canada Council for the Arts Killam Prize in Health Sciences.
Mr. Tergesen has served as Burcon's president and chief operating officer since September 2000, having held additional senior management roles with the Company since its inception as a capital pool company in 1998. He also served as a member of Burcon's board of directors for nearly fourteen years from November 1998 to September 2012. A plant protein industry veteran, Mr. Tergesen has helped guide Burcon's technology and intellectual property growth in alternative plant-based proteins.
About Burcon NutraScience Corporation
Burcon is a leader in developing functionally and nutritionally valuable plant-based proteins. The company has developed a portfolio of composition, application, and process patents originating from a core protein extraction and purification technology. Burcon's CLARISOY(R) soy protein - under license to the Archer Daniels Midland Company - offers clarity and high-quality protein nutrition for low pH beverage systems and excellent solubility and exceptionally clean flavor at any pH; Peazazz(R) is a uniquely soluble and clean-tasting pea protein; and Puratein(R), Supertein(R) and Nutratein(R) are canola protein isolates with unique functional and nutritional attributes. For more information about the company, visit www.burcon.ca.
Burcon NutraScience Corporation Announces Clos ...
Burcon NutraScience Corp.: Burcon Commences Tr ...
Burcon NutraScience Corp.: Burcon NutraScience ...
Burcon NutraScience Corp.: Burcon, Merit and N ...
Burcon NutraScience Corp.: Merit Functional Fo ...
HELMA Eigenheimbau: Klarer Kauf
Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.
Der AKTIONÄR News
22. Februar 07:00 Hebel-Depot: Neues Jahreshoch dank Nvidia – Zalando mit an Bord
21. Februar 19:03 Goldpreis nicht zu stoppen – Barrick Gold mit neuem 52-Wochen-Hoch
21. Februar 18:05 BASF-Rivale Covestro: Ans DAX-Ende durchgereicht, aber…
21. Februar 15:48 Börsenpunk: Börsenpunk: Daimler-Blues hält an / Bilibili - alles ...
21. Februar 14:44 1&1 Drillisch springt nach oben – ist das die Wende?
News im Fokus
Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2019
21. Februar 2020, 11:54
Original-Research: Media and Games Invest plc (von First Berlin Equity Research GmbH): BUY
21. Februar 2020